Search
for
Sort by
Research 31–60 of 33
- Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review
- Breast cancer in a transgender man
- Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention
- Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
- Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events
- Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
- 1094 Discovering hair loss treatments that increase the Wnt/β-catenin signaling pathway by high-throughput screening
- Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles
- Alopecia induced by CDK 4/6 Inhibitors and its Impact on the Quality of Life of Patients with advanced Breast cancer
- Real-World Safety Profile of Generic Palbociclib in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Prospective Observational Study in Iraq”
- Real-world pharmacovigilance insights into drug-induced risk of alopecia
- Kalya Research: Complementary and Alternative Medicine (CAM) Virtual Research Assistant from Biomedical Literature
- Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
- Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.
- Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
- Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer
- Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in breast cancer patients
- Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
- A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib
- Estrogen deprivation effects of endocrine therapy in breast cancer patients: Incidence, management and outcome
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
- Effect of palbociclib plus letrozole on patient-reported health-related quality of life: extended follow-up of the PALOMA-2 trial
- Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique
- Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
- Severe Lichen Planus Pigmentosus Inversus in an Elderly Female Following Intra-Articular Injections of Homeopathic Substances